These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 39203719)

  • 1. Potential Add-On Benefits of Dietary Intervention in the Treatment of Autosomal Dominant Polycystic Kidney Disease.
    Rosati E; Condello G; Tacente C; Mariani I; Tommolini V; Calvaruso L; Fulignati P; Grandaliano G; Pesce F
    Nutrients; 2024 Aug; 16(16):. PubMed ID: 39203719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketogenic Interventions in Autosomal Dominant Polycystic Kidney Disease: A Comprehensive Review of Current Evidence.
    Pezzuoli C; Biagini G; Magistroni R
    Nutrients; 2024 Aug; 16(16):. PubMed ID: 39203812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycystic Kidney Disease Diet: What is Known and What is Safe.
    Chebib FT; Nowak KL; Chonchol MB; Bing K; Ghanem A; Rahbari-Oskoui FF; Dahl NK; Mrug M
    Clin J Am Soc Nephrol; 2024 May; 19(5):664-682. PubMed ID: 37729939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.
    Nowak KL; Hopp K
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):577-584. PubMed ID: 32086281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease.
    Pickel L; Iliuta IA; Scholey J; Pei Y; Sung HK
    Adv Nutr; 2022 Mar; 13(2):652-666. PubMed ID: 34755831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease.
    Kipp KR; Rezaei M; Lin L; Dewey EC; Weimbs T
    Am J Physiol Renal Physiol; 2016 Apr; 310(8):F726-F731. PubMed ID: 26764208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is autosomal dominant polycystic kidney disease an early sweet disease?
    Dachy A; Decuypere JP; Vennekens R; Jouret F; Mekahli D
    Pediatr Nephrol; 2022 Sep; 37(9):1945-1955. PubMed ID: 34988697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary Care for ADPKD Patients: Current Status and Future Directions.
    Carriazo S; Perez-Gomez MV; Cordido A; García-González MA; Sanz AB; Ortiz A; Sanchez-Niño MD
    Nutrients; 2019 Jul; 11(7):. PubMed ID: 31336917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease.
    Oehm S; Steinke K; Schmidt J; Arjune S; Todorova P; Heinrich Lindemann C; Wöstmann F; Meyer F; Siedek F; Weimbs T; Müller RU; Grundmann F
    Nephrol Dial Transplant; 2023 Jun; 38(7):1623-1635. PubMed ID: 36423335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can ketogenic dietary interventions slow disease progression in ADPKD: what we know and what we don't.
    Ong ACM; Torra R
    Clin Kidney J; 2022 Jun; 15(6):1034-1036. PubMed ID: 35664267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketogenic dietary interventions in autosomal dominant polycystic kidney disease-a retrospective case series study: first insights into feasibility, safety and effects.
    Strubl S; Oehm S; Torres JA; Grundmann F; Haratani J; Decker M; Vuong S; Kaur Bhandal A; Methot N; Haynie-Cion R; Meyer F; Siedek F; Korst U; Müller RU; Weimbs T
    Clin Kidney J; 2022 Jun; 15(6):1079-1092. PubMed ID: 35664270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nutraceutical for Autosomal Dominant Polycystic Kidney Disease Therapy.
    Yuajit C; Chatsudthipong V
    J Med Assoc Thai; 2016 Jan; 99 Suppl 1():S97-103. PubMed ID: 26817244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.
    Torres JA; Kruger SL; Broderick C; Amarlkhagva T; Agrawal S; Dodam JR; Mrug M; Lyons LA; Weimbs T
    Cell Metab; 2019 Dec; 30(6):1007-1023.e5. PubMed ID: 31631001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Food Restriction Ameliorates the Development of Polycystic Kidney Disease.
    Warner G; Hein KZ; Nin V; Edwards M; Chini CC; Hopp K; Harris PC; Torres VE; Chini EN
    J Am Soc Nephrol; 2016 May; 27(5):1437-47. PubMed ID: 26538633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD-a randomized controlled trial.
    Cukoski S; Lindemann CH; Arjune S; Todorova P; Brecht T; Kühn A; Oehm S; Strubl S; Becker I; Kämmerer U; Torres JA; Meyer F; Schömig T; Hokamp NG; Siedek F; Gottschalk I; Benzing T; Schmidt J; Antczak P; Weimbs T; Grundmann F; Müller RU
    Cell Rep Med; 2023 Nov; 4(11):101283. PubMed ID: 37935200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease.
    Kipp KR; Kruger SL; Schimmel MF; Parker N; Shillingford JM; Leamon CP; Weimbs T
    Am J Physiol Renal Physiol; 2018 Aug; 315(2):F395-F405. PubMed ID: 29717938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis.
    He J; Zhou H; Meng J; Zhang S; Li X; Wang S; Shao G; Jin W; Geng X; Zhu S; Yang B
    Pharmacol Res; 2020 May; 155():104751. PubMed ID: 32151678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP Study): study protocol for a randomized controlled trial.
    Riegersperger M; Herkner H; Sunder-Plassmann G
    Trials; 2015 Apr; 16():182. PubMed ID: 25899445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diet and Physical Activity in Adult Dominant Polycystic Kidney Disease: A Review of the Literature.
    Capelli I; Lerario S; Aiello V; Provenzano M; Di Costanzo R; Squadrani A; Vella A; Vicennati V; Poli C; La Manna G; Baraldi O
    Nutrients; 2023 Jun; 15(11):. PubMed ID: 37299584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-hydroxybutyrate recapitulates the beneficial effects of ketogenic metabolic therapy in polycystic kidney disease.
    Torres JA; Holznecht N; Asplund DA; Kroes BC; Amarlkhagva T; Haeffner MM; Sharpe EH; Koestner S; Strubl S; Schimmel MF; Kruger S; Agrawal S; Aceves BA; Thangaraju M; Weimbs T
    iScience; 2024 Sep; 27(9):110773. PubMed ID: 39314240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.